We are live on ! Find out more
ATXI icon

Avenue Therapeutics

Delisted

ATXI was delisted on the 18th of March, 2025.

12 hedge funds and large institutions have $8.59M invested in Avenue Therapeutics in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

707% more capital inflows, than outflows

Capital inflows: $1.19M | Capital outflows: $148K

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

9% more funds holding

Funds holding: 11 → 12 (+1)

1.21% more ownership

Funds ownership: 7.03% → 8.23% (+1.2%)

Holders
12
Holders Change
+1
Holders Change %
+9.09%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
5
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ATXI Hedge Fund Activity: Q2 2019 in Review

12 of the 4,627 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics (ATXI) for Q2 2019, worth a combined $8.59M — up 56% from $5.51M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new ATXI positions and 0 closed out — a net gain of 1 holder — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Opaleye Management, adding an estimated $672K. The largest seller was EAM Investors, cutting an estimated $86.8K.

  • 12 institutional investors held Avenue Therapeutics (ATXI) as of Q2 2019, up from 11 in Q1 2019.
  • Funds reported $8.59M of Avenue Therapeutics stock for Q2 2019, up 56% quarter-over-quarter.
  • 1 fund opened new Avenue Therapeutics positions in Q2 2019 and 0 closed out, a net change of +1 holder.
  • The largest Avenue Therapeutics buyer in Q2 2019 was Opaleye Management, an estimated $672K added.
  • The largest Avenue Therapeutics seller in Q2 2019 was EAM Investors, an estimated $86.8K sold.

Based on aggregated 13F filings for Q2 2019.